Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 1,100 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.00, for a total transaction of $94,600.00. Following the transaction, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at $22,781,400. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Jane Huang also recently made the following trade(s):
- On Thursday, November 16th, Jane Huang sold 600 shares of Beigene stock. The stock was sold at an average price of $85.00, for a total transaction of $51,000.00.
- On Monday, November 20th, Jane Huang sold 1,600 shares of Beigene stock. The stock was sold at an average price of $86.25, for a total transaction of $138,000.00.
Shares of Beigene Ltd (BGNE) traded down $3.61 during midday trading on Thursday, reaching $92.76. 288,100 shares of the company traded hands, compared to its average volume of 204,903. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. Beigene Ltd has a 12 month low of $26.43 and a 12 month high of $118.95.
Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Beigene during the 2nd quarter worth $111,000. Quantbot Technologies LP acquired a new stake in Beigene during the 3rd quarter worth $160,000. Renaissance Technologies LLC acquired a new stake in Beigene during the 1st quarter worth $238,000. Profund Advisors LLC acquired a new stake in Beigene during the 2nd quarter worth $248,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Beigene during the 3rd quarter worth $248,000. 55.34% of the stock is currently owned by institutional investors.
A number of equities analysts have issued reports on BGNE shares. Maxim Group set a $120.00 price target on shares of Beigene and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Cowen reaffirmed a “buy” rating on shares of Beigene in a report on Tuesday, November 14th. Zacks Investment Research raised shares of Beigene from a “hold” rating to a “buy” rating and set a $115.00 target price for the company in a report on Tuesday, October 3rd. Goldman Sachs Group reaffirmed a “buy” rating and set a $86.00 target price (up from $43.00) on shares of Beigene in a report on Tuesday, August 15th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $83.00 target price (up from $58.00) on shares of Beigene in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $96.67.
COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.com-unik.info/2017/12/07/jane-huang-sells-1100-shares-of-beigene-ltd-bgne-stock.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
What are top analysts saying about Beigene Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Beigene Ltd and related companies.